CJC 1295 with DAC Peptide – UK Laboratory Research Grade

If your facility is looking to study growth hormone secretagogues, CJC 1295 with DAC offers extended biological half-life compared to standard modified GRF (1-29). By incorporating the Drug Affinity Complex (DAC), this synthetic tetrasubstituted peptide analogue of Growth Hormone Releasing Hormone (GHRH) binds covalently to circulating albumin post-reconstitution, extending its research half-life to approximately 6 to 8 days.

Whether analyzing GH release dynamics, receptor binding affinity, or cell culture response, understanding proper CJC 1295 with DAC dosage parameters and reconstitution procedures ensures high experimental accuracy in laboratory models.

Technical Specifications & Chemical Profile

Our high-purity CJC-1295 with DAC reference material is produced under strict solid-phase peptide synthesis (SPPS) standards:

Chemical Property	Technical Detail
Product Name	CJC-1295 with DAC (Drug Affinity Complex)
CAS Registry Number	863288-34-0
Molecular Formula	C₁₆₅H₂₆₉N₄₇O₄₆
Molecular Weight	3647.28 g/mol
Sequence	Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(DAC)-NH₂
Purity Grade	≥99.0% (HPLC & Mass Spectrometry Verified)
Physical Appearance	Lyophilized (Freeze-Dried) White Powder
Storage (Unopened)	Store at -20°C (desiccated, protected from light)

CJC 1295 with DAC Dosage Parameters in Scientific Literature

In clinical trials and peer-reviewed literature, the presence of the Drug Affinity Complex fundamentally alters the administration protocol compared to CJC-1295 No DAC (modified GRF 1-29).

Research Dosage Guidelines

• Standard Weekly Study Dose: In human clinical trials evaluating GH and IGF-1 secretion, CJC 1295 with DAC dosage studies examined ranges from 1000 mcg to 2000 mcg (1 mg to 2 mg) per week, administered either as a single weekly dose or split into two bi-weekly applications.

• Extended Half-Life: Unlike CJC-1295 No DAC (which has a short half-life of 30 minutes requiring multiple daily injections), the DAC addition allows continuous baseline elevation of growth hormone for up to 8 days.

• IGF-1 Response: Studies demonstrate that a single 30 mcg/kg to 60 mcg/kg CJC 1295 with DAC dosage results in sustained, dose-dependent increases in plasma growth hormone and IGF-1 levels for up to 14 days post-injection.

Reconstitution & Laboratory Handling

1. Equilibration: Bring the lyophilized vial to room temperature before adding liquid solvents to prevent moisture condensation.

2. Reconstitution: Using a sterile syringe, slowly introduce 1 ml or 2 ml of Bacteriostatic Water (0.9% benzyl alcohol) against the inner glass wall of the vial.

3. Dissolution: Gently swirl the glass container until the white powder dissolves completely. Do not shake vigorously, as structural protein bonds can shear under mechanical stress.

4. Storage: Keep reconstituted solutions refrigerated between 2°C and 8°C. For extended storage of liquid aliquots, freeze at -20°C to prevent hydrolysis.

Frequently Asked Questions

What is the difference between CJC 1295 with DAC and CJC 1295 without DAC?

CJC 1295 without DAC (Mod GRF 1-29) has a short half-life of roughly 30 minutes and requires daily or multi-daily application. CJC 1295 with DAC contains a lysine linker attached to maleimidopropionic acid, enabling it to bind to blood albumin and extend its half-life to 6–8 days.

What is the typical CJC 1295 with DAC dosage evaluated in research?

Most research protocols evaluate a total weekly CJC-1295 with DAC dosage of 2000 mcg (2 mg), often administered as 1000 mcg twice weekly to maintain stable plasma peptide concentrations.

Does CJC 1295 with DAC require a GHRP like Ipamorelin?

In laboratory research, CJC 1295 with DAC is frequently studied both independently and alongside Growth Hormone Releasing Peptides (GHRPs) like Ipamorelin or GHRP-2 to evaluate synergistic pulse amplitude in growth hormone secretion.